Other languages NGM Biopharmaceuticals, Inc.

Equities

NGM

US62921N1054

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-04 pm EDT			5-day change	1st Jan Change
1.54 ^USD	-1.28%		0.00%	+79.28%

Apr. 05	NGM Biopharmaceuticals, Inc.(NasdaqGM:NGM) dropped from NASDAQ Composite Index	CI
Apr. 05	The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. from other group of shareholders.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. from other group of shareholders.	Apr. 04
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 26
Sector Update: Health Care Stocks Weaker Monday Afternoon	Feb. 26
Sector Update: Health Care	Feb. 26
NGM Biopharmaceuticals Enters Merger Deal With Affiliates of The Column Group	Feb. 26
NGM Biopharmaceuticals Provides Update on Cancer Treatment Trial -- Shares Rise	Jan. 09
NGM Bio Announces New Clinical Data from Ongoing Trial of Ngm707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and Ngm120 to Focus on Rare Conditions with Significant Unmet Need	Jan. 09
NGM Biopharmaceuticals Stock Soars as Shareholder Group Expresses Takeover Interest	Jan. 02
NGM Biopharmaceuticals Receives Non-Binding Expression of Interest from Column Group	Jan. 01
NGM Biopharmaceuticals Says Phase 2b Trial of Potential Cirrhosis Treatment Meets Primary Endpoint	Nov. 13
NGM Biopharmaceuticals, Inc. Presents Positive Phase 2b Results from the Alpha 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting	Nov. 13
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Ngm Biopharmaceuticals, Inc. Appoints Irene Perlich as Principal Accounting Officer, Effective September 15, 2023	23-09-11
NGM Biopharmaceuticals, Inc. Announces Appointment of Irene Perlich as Principal Accounting Officer, Effective September 15, 2023	23-08-11
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
Jin-Long Chen, Ph.D. Resigns as Chief Scientific Officer of NGM Biopharmaceuticals, Inc., and as A Member of the Board	23-04-04
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages NGM Biopharmaceuticals, Inc.

Equities

NGM

US62921N1054

Other languages

Filters